MigVax receives funding award from CEPI to develop ‘variant-proof’ COVID-19 vaccines


We are honored to be one of the first two projects to receive funding from CEPI’s visionary program aimed at accelerating the development of broadly protective vaccines against coronaviruses and their variants. 

This grant will help us speed MigVax-101, the health establishment's first tablet-based vaccine booster, to market, enabling a breakthrough in the cost and reach of mass vaccination initiatives. We believe this will be an important part of the world’s transition from panic mode to a ’new normal’, in which pandemics do not necessarily shut down entire economies.

For more information: https://cepi.net/news_cepi/cepi-announces-first-funding-awards-in-quest-to-develop-variant-proof-covid-19-vaccines